Assessment of the N-Acetyl cysteine effect on diabetic foot ulcers

Phase 3

• Conditions: Diabetic foot ulcer.; Personal history of diabetic foot ulcer; Z86.31

• Registration Number: IRCT20220928056051N2
• Lead Sponsor: Oroumia University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Age above 18 years
Grade 3 or 4 diabetic foot ulcer according to Wagner criteria

Exclusion Criteria

Allergy to N-Acetyl cysteine and sulfur products
Pregnancy and breastfeeding
Other causes of ulcers except diabetes include trauma and others
A generated- ulcers skin disease
Impossibility of taking tablets orally
Patients treated with chemotherapy or radiotherapy drugs
Taking drugs such as: corticosteroids at a minimum dose equivalent to 40 milligrams of prednisolone, mycophenolate, cyclosporine, tacrolimus, rituximab
Hospitalized for a diabetic foot ulcer in the last month and receiving injection antibiotic treatment
Stenosis and severe cramping of the lower limbs vessels based on vascular sonography
Chronic alcohol consumption of more than 250 cc daily

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Wound size. Timepoint: Before and 14 days after the intervention. Method of measurement: Wound area in cm2 based on imaging.;Wound Number. Timepoint: Before and 14 days after the intervention. Method of measurement: Clinical examination.;Healing time. Timepoint: After intervention. Method of measurement: Days.

Secondary Outcome Measures

Name	Time	Method
Duration of hospitalization. Timepoint: After intervention. Method of measurement: Days.